Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,387JPY
23 Apr 2019
Change (% chg)

¥88 (+1.40%)
Prev Close
¥6,299
Open
¥6,353
Day's High
¥6,406
Day's Low
¥6,337
Volume
920,800
Avg. Vol
1,247,917
52-wk High
¥7,796
52-wk Low
¥5,410

Select another date:

Wed, Jan 23 2019

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO, Oct 29 Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

FDA approves first new flu drug in almost two decades

Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

CORRECTED-FDA approves first new flu drug in almost two decades

Oct 24 Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

Select another date: